

ANNEXa-I Deep Dive: Part I References

Special Guests: Scott Dietrich, PharmD, BCCCP
Brian Gilbert, PharmD, MBA, BCCCP, FCCM, FNCS
Todd Miano, PharmD, PhD, FCCM

Featured Article

ANNEXA-I Investigators. Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. *N Engl J Med*. 2024 May 16;390(19):1745-1755. <https://pubmed.ncbi.nlm.nih.gov/38749032/>

Articles Referenced

Siegel DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. *N Engl J Med*. 2015 Dec 17;373(25):2413-24. <https://pubmed.ncbi.nlm.nih.gov/26559317/>

Singer AJ, Concha M, Williams J, Brown CS, et al. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study. *West J Emerg Med*. 2023 Sep;24(5):939-949. <https://pubmed.ncbi.nlm.nih.gov/37788035/>

Dobesh PP, Fermann GJ, Christoph MJ, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. *Res Pract Thromb Haemost*. 2023 Aug 30;7(6):102192. <https://pubmed.ncbi.nlm.nih.gov/37753225/>

Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. *N Engl J Med*. 2017 Aug 3;377(5):431-441. <https://pubmed.ncbi.nlm.nih.gov/28693366/>

Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med*. 2001 Mar 8;344(10):699-709. <https://pubmed.ncbi.nlm.nih.gov/11236773/>

van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med*. 2001 Nov 8;345(19):1359-67. <https://pubmed.ncbi.nlm.nih.gov/11794168/>

Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology*. 2006 Apr 25;66(8):1175-81. <https://pubmed.ncbi.nlm.nih.gov/16636233/>

INTERACT1 Investigators. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. *Neurology*. 2012 Jul 24;79(4):314-9. <https://pubmed.ncbi.nlm.nih.gov/22744655/>

Kuohn LR, Witsch J, Steiner T, et al. Early Deterioration, Hematoma Expansion, and Outcomes in Deep Versus Lobar Intracerebral Hemorrhage: The FAST Trial. *Stroke*. 2022 Aug;53(8):2441-2448. <https://pubmed.ncbi.nlm.nih.gov/35360929/>

Panos NG, Cook AM, John S, Jones GM; Neurocritical Care Society (NCS) Pharmacy Study Group. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. *Circulation*. 2020 May 26;141(21):1681-1689. <https://pubmed.ncbi.nlm.nih.gov/32264698/>